Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved
- PMID: 16257564
- DOI: 10.1016/j.biocel.2005.08.021
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved
Abstract
Fibrosis, defined as the excessive deposition of extracellular matrix in an organ, is the main complication of chronic liver damage. Its endpoint is cirrhosis, which is responsible for significant morbidity and mortality. The accumulation of extracellular matrix observed in fibrosis and cirrhosis is due to the activation of fibroblasts, which acquire a myofibroblastic phenotype. Myofibroblasts are absent from normal liver. They are produced by the activation of precursor cells, such as hepatic stellate cells and portal fibroblasts. These fibrogenic cells are distributed differently in the hepatic lobule: the hepatic stellate cells resemble pericytes and are located along the sinusoids, in the Disse space between the endothelium and the hepatocytes, whereas the portal fibroblasts are embedded in the portal tract connective tissue around portal structures (vessels and biliary structures). Differences have been reported between these two fibrogenic cell populations, in the mechanisms leading to myofibroblastic differentiation, activation and "deactivation", but confirmation is required. Second-layer cells surrounding centrolobular veins, fibroblasts present in the Glisson capsule surrounding the liver, and vascular smooth muscle cells may also express a myofibroblastic phenotype and may be involved in fibrogenesis. It is now widely accepted that the various types of lesion (e.g., lesions caused by alcohol abuse and viral hepatitis) leading to liver fibrosis involve specific fibrogenic cell subpopulations. The biological and biochemical characterisation of these cells is thus essential if we are to understand the mechanisms underlying the progressive development of excessive scarring in the liver. These cells also differ in proliferative and apoptotic capacity, at least in vitro. All this information is required for the development of treatments specifically and efficiently targeting the cells responsible for the development of fibrosis/cirrhosis.
Similar articles
-
Inflammation, damage repair and liver fibrosis--role of cytokines and different cell types.Z Gastroenterol. 2007 Jan;45(1):77-86. doi: 10.1055/s-2006-927395. Z Gastroenterol. 2007. PMID: 17236124 Review.
-
Liver fibrosis: from the bench to clinical targets.Dig Liver Dis. 2004 Apr;36(4):231-42. doi: 10.1016/j.dld.2004.01.003. Dig Liver Dis. 2004. PMID: 15115333 Review.
-
Activated hepatic stellate cells in liver cirrhosis. A morphologic and morphometrical study.Ital J Anat Embryol. 2004 Oct-Dec;109(4):225-38. Ital J Anat Embryol. 2004. PMID: 15717457
-
Liver fibrosis.Biochem J. 2008 Apr 1;411(1):1-18. doi: 10.1042/BJ20071570. Biochem J. 2008. PMID: 18333835 Review.
-
Cirrhosis--can we reverse hepatic fibrosis?Eur J Surg Suppl. 2002;(587):100-12. Eur J Surg Suppl. 2002. PMID: 16144208 Review.
Cited by
-
The myofibroblast, multiple origins for major roles in normal and pathological tissue repair.Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S5. doi: 10.1186/1755-1536-5-S1-S5. eCollection 2012. Fibrogenesis Tissue Repair. 2012. PMID: 23259712 Free PMC article.
-
Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.J Pediatr Gastroenterol Nutr. 2010 Jun;50(6):639-44. doi: 10.1097/MPG.0b013e3181cc80e4. J Pediatr Gastroenterol Nutr. 2010. PMID: 20400910 Free PMC article.
-
Collagen Type III as a Possible Blood Biomarker of Fibrosis in Equine Endometrium.Animals (Basel). 2022 Jul 21;12(14):1854. doi: 10.3390/ani12141854. Animals (Basel). 2022. PMID: 35883401 Free PMC article.
-
Employment of gene expression profiling to identify transcriptional regulators of hepatic stellate cells.Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S12. doi: 10.1186/1755-1536-5-S1-S12. eCollection 2012. Fibrogenesis Tissue Repair. 2012. PMID: 23259668 Free PMC article.
-
Current status of novel antifibrotic therapies in patients with chronic liver disease.Therap Adv Gastroenterol. 2011 Nov;4(6):391-417. doi: 10.1177/1756283X11413002. Therap Adv Gastroenterol. 2011. PMID: 22043231 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical